Glucocorticoids (GCs) are the mainstay of treatment for patients with polymyalgia rheumatica (PMR).¹ Despite their efficacy, GCs are associated with well-known adverse events and a substantial proportion of patients with PMR do not respond adequately, or are refractory, to initial GC treatment. GC-sparing agents in PMR are limited to methotrexate (MTX).¹.

中文翻译：

---

阿巴西普作为难治性多肌痛风湿病的辅助治疗。

糖皮质激素（GCs）是风湿性多肌痛（PMR）患者的主要治疗方法。¹尽管 GC 有效，但它们与众所周知的不良事件相关，并且相当大比例的 PMR 患者对初始 GC 治疗没有充分反应或难以治疗。PMR 中的 GC 保留剂仅限于甲氨蝶呤 (MTX)。¹ .